Elix’s Innovative Approach to PCOS Management Highlights Traditional Chinese Medicine

NEW YORK, Sept. 19, 2024 /PRNewswire/ — Elix, a pioneering digital platform integrating Traditional Chinese Medicine (TCM) with advanced technology, is committed to challenging medical misogyny with its latest initiative. In a concerted effort to combat Polycystic Ovary Syndrome (PCOS)—a condition that is significantly under-researched—Elix has funded an independent, groundbreaking clinical study. Furthermore, it is launching a campaign demanding greater focus on PCOS within the medical community, aiming to destigmatize these conditions so that sufferers feel less isolated.

The limited funding, research, and resources available have left approximately 12 million people struggling to manage PCOS symptoms effectively. With no FDA-approved drug specifically targeting PCOS, current treatments are primarily off-label and have potential side effects. Despite affecting up to 20% of individuals of reproductive age, with up to 70% remaining undiagnosed globally (according to WHO), PCOS receives less than 0.84% of the medical research funding allocated to conditions like erectile dysfunction.

Through this study, Elix aims to generate critical conversations around PCOS, underscoring the urgent need for increased research, diagnosis, and treatment development. In recognition of PCOS Awareness Month, Elix proudly announces the results of its independent clinical study examining the effectiveness of its personalized TCM formulations in alleviating PCOS symptoms.

The clinical study evaluated two of Elix’s flagship products—Cycle Balance and Daily Harmony. These herbal supplements, rooted in 5,000 years of TCM research, address inflammation and hormonal imbalances associated with PCOS. Conducted over six months, the trial involved 70 participants aged 18-36 diagnosed with PCOS, divided into two groups based on hormonal birth control usage.

Elix is dedicated to extending the conversation on PCOS beyond this study. Throughout September and October, the brand will share compelling stories of individuals affected by PCOS across social media, launching an advocacy campaign in the process. “Thank you to the Elix community members who support a fusion of Eastern and Western approaches,” stated Lulu Ge, Founder and CEO of Elix. “This study is a significant milestone in advancing alternative treatment options for the millions affected by PCOS.”

Dr. Liem Le, DAOM, MS, a Medical Advisor for Elix, expressed excitement about the clinical trial results, stating that TCM’s wisdom is validated powerfully through this new data. Dr. Jessica Ritch, OBGYN, highlighted the importance of having a natural alternative that is effective and backed by clinical data, offering patients who cannot tolerate birth control an option for managing their PCOS symptoms.

For more details regarding Elix’s initiatives and to join the advocacy for enhanced PCOS awareness and research, individuals are encouraged to visit their website and engage with their campaign on social media platforms.

ABOUT ELIX  Elix is the first digital platform to personalize Traditional Chinese Medicine (TCM) by applying modern technology, blending time-tested knowledge, personalized medicinal botanicals, behavioral interventions, and clinical research to promote healing at the root.